Committees for Via Oncology meet frequently to update pathway platforms and support the growing needs of physicians, according to Kathleen Lokay.
Committees for Via Oncology meet frequently to update pathway platforms and support the growing needs of physicians, according to Kathleen Lokay.
Transcript
How frequently are your pathways platforms updated to reflect the latest research developments in oncology, especially in the context of using diagnostic tests?
Our medical oncology committees actually meet the most frequently of all. Radiation and surgical oncology don’t meet as often because there’s not as much data changing. But the medical oncology committees meet every quarter. There’s just that much going on in oncology. Then if there is something groundbreaking in between a meeting the committees can always call an ad hoc meeting. So we really want to make sure that we’re addressing new data frequently and that we really keep the pathways up to speed and that new data includes diagnostic tests. So we will be incorporating new biomarkers in virtually every meeting as new data comes out.
Is there anything Via Oncology is thinking about doing next that physicians are looking for?
The thing that we don’t have so much now is precision medicine in the sense of things that are not really standardized care. So if it’s not standardized care, we historical don’t put it in the pathways but we’re increasingly getting our practices asking us to help them with those places where they’re doing genomic sequencing and wanting support for that and wanting to then have their results then be matched with their clinical trials. So it’s stepping outside of what has historically been a more standardized healthcare pathway into something more researched but something that is clearly becoming a bigger and bigger part of practice.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More